SCHEMBL4611976

SCHEMBL4611976

O=C(Cc1ccc(NC(=O)c2ccccc2)cc1)NO

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.71
MEN1 O00255 6/20 0.71
POLB P06746 3/20 0.71
ALDH1A1 P00352 1/20 0.71
HPGD P15428 1/20 0.71
KDM4E B2RXH2 3/20 0.68
HTT P42858 1/20 0.68
TDP1 Q9NUW8 1/20 0.68
HDAC8 Q9BY41 3/20 0.62
HDAC6 Q9UBN7 3/20 0.62
NR1H4 Q96RI1 2/20 0.61
HDAC2 Q92769 2/20 0.60
HDAC3 O15379 1/20 0.60
HDAC4 P56524 1/20 0.60
HDAC1 Q13547 1/20 0.60
HDAC7 Q8WUI4 1/20 0.60
HDAC10 Q969S8 1/20 0.60
HDAC11 Q96DB2 1/20 0.60
HDAC9 Q9UKV0 1/20 0.60
HDAC5 Q9UQL6 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4931868 0.88 MEN1 (0.64) KMT2AMEN1POLBALDH1A1HPGD
SCHEMBL8143801 0.85 NR1H4 (0.82) KMT2AMEN1POLBALDH1A1HPGD
SCHEMBL14811482 0.85 HDAC8 (0.79) KMT2AMEN1ALDH1A1HPGDHDAC8
SCHEMBL5154816 0.84 PTPN1 (0.69) KMT2AMEN1POLBALDH1A1HPGD
SCHEMBL1233330 0.84 MEN1 (0.70) KMT2AMEN1POLBALDH1A1HPGD
SCHEMBL5438741 0.84 RAB9A (0.67) KMT2AMEN1POLBALDH1A1HPGD
SCHEMBL4659243 0.84 HDAC3 (0.57) KMT2AMEN1POLBALDH1A1HPGD
SCHEMBL22664681 0.83 HDAC1 (0.69) KMT2AMEN1POLBALDH1A1HPGD
SCHEMBL4656074 0.83 MEN1 (0.76) KMT2AMEN1POLBALDH1A1HPGD
SCHEMBL27997273 0.82 KMT2A (0.68) KMT2AMEN1POLBALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013041407-A1 HYDROXAMIC ACIDS AS HDAC6 INHIBITORS CELLZOME AG (DE) 2013-03-28 WO claimed
EP-1660437-B1 HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF AMOREPACIFIC CORP (KR) 2008-10-15 EP claimed
US-7282522-B2 Hydroxamic acid derivatives and the method for preparing thereof AMOREPACIFIC CORPORATION (KR) 2007-10-16 US claimed
US-20060252834-A1 Hydroxamic acid derivatives and the method for preparing thereof AMOREPACIFIC CORPORATION (KR) 2006-11-09 US claimed
EP-1660437-A4 HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF AMOREPACIFIC CORP (KR) 2006-09-20 EP claimed
EP-1660437-A1 HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF Amorepacific Corporation (KR) 2006-05-31 EP claimed
WO-2005019162-A1 HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF AMOREPACIFIC CORPORATION (KR) 2005-03-03 WO claimed
WO-2013041407-A1 HYDROXAMIC ACIDS AS HDAC6 INHIBITORS CELLZOME AG (DE) 2013-03-28 WO disclosed
WO-2013041407-A1 HYDROXAMIC ACIDS AS HDAC6 INHIBITORS CELLZOME AG (DE) 2013-03-28 WO disclosed
EP-1660437-B1 HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF AMOREPACIFIC CORP (KR) 2008-10-15 EP disclosed
US-7282522-B2 Hydroxamic acid derivatives and the method for preparing thereof AMOREPACIFIC CORPORATION (KR) 2007-10-16 US disclosed
US-20060252834-A1 Hydroxamic acid derivatives and the method for preparing thereof AMOREPACIFIC CORPORATION (KR) 2006-11-09 US disclosed
EP-1660437-A4 HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF AMOREPACIFIC CORP (KR) 2006-09-20 EP disclosed
EP-1660437-A1 HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF Amorepacific Corporation (KR) 2006-05-31 EP disclosed
WO-2005019162-A1 HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF AMOREPACIFIC CORPORATION (KR) 2005-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252834-A1 Hydroxamic acid derivatives and the method for preparing thereof HDAC7, SIRT7, HCAR1 KMT2A 3483/4885MEN1 3786/4885POLB 2248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.